First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

The drug that will be investigated in the trial is an antibody, GEN3018. Since this is the first trial of GEN3018 in humans, the main purpose is to evaluate safety. In addition to safety, the trial will determine the recommended GEN3018 dose(s) to be tested in a larger group of participants and assess preliminary anti-tumor activity of GEN3018. GEN3018 will be studied in refractory (resistant to treatment) or relapsed (disease has returned) acute myeloid leukemia (also known as R/R AML) and refractory or relapsed higher-risk myelodysplastic syndrome (also known as R/R HR-MDS). The trial consis

Trial Details

NCT ID
NCT07384715
Phase
PHASE1
Sponsor
Genmab
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • GEN3018
Locations (sample)
  • Aarhus, Denmark, Denmark|56.15674,10.21076
  • Copenhagen, Denmark, Denmark|55.67594,12.56553
  • Bergamo, Italy|45.69601,9.66721
  • Milan, Italy|42.78235,12.59836
  • Pisa, Italy|43.70853,10.4036

Key Eligibility Criteria

  • All Participants:
  • Be at least 18 years of age at the time of signing informed consent form (ICF).
  • Participant's life expectancy at screening is judged to be at least 3 months.
  • Must have fresh bone marrow samples collected at screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →